ArticleACS omega2025
Comprehensive Characterization and Biological and Safety Evaluation of Zinc Oxide-Curcumin Nanoconjugates: Unraveling Synergistic Effects for Enhanced Therapeutic Applications.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acrylamide-Induced Neurotoxicity Is Mitigated by Curcumin and Its Nano Lipid Carrier Formulation in Albino Rats.Environmental toxicology · 2026Article
- Metformin and cRGDfc-Modified Nanoparticles Loaded with Curcumin for Age-Related Macular Degeneration: In Vitro Pharmacodynamics and Molecular Mechanisms.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles have been widely synthesized and used in various biological applications. Among the minerals, zinc (Zn) alters numerous biological pathways, and curcumin (Cur) functions mainly as the antimicrobial, anti-inflammatory, and anticancerous agent. In this study, nano-zinc oxide (nZnO), nano-curcumin (nCur), and its conjugate (nZnOcur) were synthesized through the chemical reduction method. The particles were characterized using UV-visible (UV-visible) spectroscopy, Fourier transform infrared (FTIR) spectroscopy, X-ray diffraction (XRD), scanning electron microscopy-energy-dispersive X-ray spectroscopy (SEM-EDS), high-resolution transmission electron microscopy (HR-TEM), dynamic light scattering (DLS), and ζ-potential measurements. The UV-visible spectrum revealed that nZnO had an absorbance peak at 370 nm, while nCur had peaks at 400-600 nm, and the nZnOcur conjugate had peaks at 550-650 nm and a smaller peak in the 300-400 nm range. The key functional groups identified by FTIR confirm the successful conjugation of nZnOcur nanoparticles. XRD patterns indicated the crystalline wurtzite phase of nZnO with variations in peak intensity, suggesting structural changes upon curcumin incorporation. SEM-EDS and DLS analyses provided average particle sizes of 88.41 and 122 nm; 53.81 and 98 nm; 43.41 and 102 nm for nZnO, nCur, and nZnOcur conjugate, respectively. HR-TEM images showed that nZnO (∼70 nm, spherical) transformed into rod-like nZnOcur (∼105 nm) upon conjugation with curcumin. nZnOcur had higher antibacterial activity against bacterial strains, demonstrating synergistic effects. The antioxidant capacity was greater in both nCur and nZnOcur conjugates, while anti-inflammatory assays indicated significant protein denaturation inhibition with all three nanoparticles. Cytotoxicity tests revealed that nZnO had higher toxicity, and the acute oral toxicity study indicated nZnOcur conjugate as least toxic, with LD
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.